H04.153 Secondary lacrimal gland atrophy, bilateral lacrimal glands

Name of the Condition

• Secondary Lacrimal Gland Atrophy, Bilateral Lacrimal Glands (ICD-10 code: H04.153)

Summary

Secondary lacrimal gland atrophy, bilateral lacrimal glands, refers to the degeneration or shrinkage of both lacrimal glands due to an underlying condition or external factor, rather than a primary disorder of the glands themselves. This condition can reduce tear production, leading to dry eye symptoms or other ocular complications. The lacrimal glands are critical for maintaining ocular surface health, and their atrophy may impact tear quality or quantity.

Causes

Causes include systemic diseases, chronic inflammation, or external factors that affect gland function. Examples are autoimmune disorders (e.g., Sjögren's syndrome), infections, radiation exposure, or trauma to the glands. Certain medications or surgical interventions near the glands may also contribute to secondary atrophy.

Risk Factors

Risk factors depend on the underlying cause but may include a history of autoimmune disease, prior radiation therapy to the head or eye area, chronic inflammatory conditions, or prolonged use of medications that suppress gland function. Age-related changes or genetic predisposition to gland degeneration may also play a role.

Symptoms

Symptoms can include persistent dry eye, eye irritation, redness, or a sensation of grittiness. Reduced tear production may lead to discomfort, blurred vision, or increased sensitivity to light. Bilateral involvement may result in more pronounced symptoms affecting both eyes.

Diagnosis

Diagnosis typically involves a clinical evaluation, including a review of medical history and symptoms. Ophthalmic examination may assess tear production (e.g., Schirmer test) and ocular surface health. Imaging studies or biopsy may be used to identify underlying causes or confirm gland atrophy.

Treatment Options

Treatment focuses on addressing the underlying cause and managing symptoms. Options may include artificial tears, anti-inflammatory medications, or immunosuppressants for autoimmune conditions. In severe cases, surgical interventions or punctal occlusion may be considered to preserve tear film.

Prognosis and Follow-Up

Prognosis depends on the underlying cause and response to treatment. Regular follow-up with an ophthalmologist is recommended to monitor tear production, ocular surface health, and adjust management as needed. Early intervention may help prevent complications.

Complications

Complications can include chronic dry eye, corneal damage, or increased risk of eye infections due to reduced tear production. Severe atrophy may lead to persistent discomfort or vision impairment if left untreated.

Lifestyle & Prevention

Lifestyle measures may include using humidifiers, avoiding dry environments, and protecting eyes from wind or irritants. Preventive strategies focus on managing underlying conditions (e.g., autoimmune disease) and avoiding known triggers like radiation exposure or certain medications.

When to Seek Professional Help

Seek medical attention if symptoms worsen, new eye pain or vision changes occur, or if dry eye symptoms persist despite over-the-counter treatments. Prompt evaluation is important to identify and address underlying causes.

Tips for Medical Coders

Document the bilateral nature of the condition and any associated underlying causes or contributing factors. Ensure clinical documentation supports the diagnosis and specifies involvement of both lacrimal glands. Code H04.153 is specific to bilateral secondary lacrimal gland atrophy; verify no other codes are needed for related conditions.